Delfi Diagnostics is a startup based in the United States, 2 tracked investors.
Based in the United States, Delfi Diagnostics is a startup founded in 2018. Brouky records 2 investors associated with the company.
Delfi Diagnostics develops AI-driven liquid biopsy tests that analyze cell-free DNA fragmentation patterns from blood samples to detect lung cancer early and monitor treatment.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.